Oriana Miltiadous, MD

Pediatric Hematology/Oncology Clinical Instructor

Oriana Miltiadous, MD

Pediatric Hematology/Oncology Clinical Instructor
Oriana Miltiadous, MD

Office Phone


Start Year


Project description

My research focus is on microbiome and outcomes after hematopoietic transplantation. Our group previously published that gut microbiome is associated with mortality and graft vs host disease after hematopoietic transplantation. I am investigating this link by further exploring microbiota metabolites and their effects on the incidence of graft vs host disease, as well as microbiota composition and immune recovery. Our work was submitted to Blood (Miltiadous O et al. Early intestinal microbial features are associated with CD4 T cell recovery after allogeneic hematopoietic transplant).

I am also exploring the links of microbiota with outcomes of pediatric cancer patients. I am evaluating how microbiome composition affects remission rates in pediatric patients with neuroblastoma undergoing therapy and how is this affecting long term outcomes.

The main questions I seek to address are:

  • How is the microbiome associated with outcomes after hematopoietic transplantation ?
  • How is the microbiome affecting clinical outcomes in pediatric patients with cancer ?

To investigate this, I am using computational tools to analyze of 16s rRNA sequencing, shotgun and metabolomics and correlate with clinical outcomes. This work is aimed to identify targets for new therapeutic interventions targeted at optimizing intestinal microbiota composition, improving treatment responses while minimizing treatment toxicities in patients with cancer and recipients of hematopoietic transplantation.


  • Tow Center for Developmental Oncology Career Development Award (2022)
  • Michael Goldberg fellow (2021)
  • American Society of Clinical Oncology – Young Investigator Award (2020)
  • Collaborative Pediatric Research Program Award – Batcole foundation (2020)
  • Hyundai Hope on Wheels – Young Investigator Award (2020)
  • End kids Cancer (2019)


  • Michael Goldberg fellow (2021)
  • American Society of Clinical Oncology – Young Investigator Award (2020)
  • Hyundai Hope on Wheels – Young Investigator Award (2020)

Invited Speaker

  • American Society for Transplantation and Cellular Therapy (TCT): Intestinal microbiota features are associated with CD4+ T cell recovery after allogeneic hematopoietic cell transplantation (2021)
  • International Pediatric Oncology Society: Prognostic significance of ATRX genetic aberrations in Neuroblastoma (2019)


  • Member, American Association of Cancer Research (AACR)
  • Member, American Academy of Pediatrics (AAP)
  • Member, American Society of Clinical Oncology (ASCO)
  • Member, Children’s Oncology Group (COG)
  • Member of Fellowship Council Committee


  • MD, University of Athens Medical School (2011)
  • Resident in pediatrics, Miami Children’s Hospital (2017)
  • Fellow in pediatric hematology/oncology, Memorial Sloan Kettering Cancer Center – New York Presbyterial/Weill Cornell Medical Center (2020)


View a full listing of Oriana Miltiadous’ journal articles.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Oriana Miltiadous discloses the following relationships and financial interests:

No disclosures meeting criteria for time period

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures